The use of prostaglandin analogs in the uveitic patient

Seminars in Ophthalmology

Volumn 26, Issue 4-5, 2011, Pages 285-289

  Horsley, Michael B ^a   Chen, Teresa C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cystoid macular edema; Herpes simplex keratitis; Prostaglandin analogs; Uveitis

Indexed keywords

BIMATOPROST; DORZOLAMIDE PLUS TIMOLOL; LATANOPROST; PROSTAGLANDIN DERIVATIVE; TIMOLOL; TRAVOPROST; UNOPROSTONE ISOPROPYL ESTER;

ARTICLE; ATROPHY; CONJUNCTIVAL HYPEREMIA; DRUG MEGADOSE; EYE INFLAMMATION; GLAUCOMA; HERPES SIMPLEX KERATITIS; HUMAN; INTRAOCULAR INFLAMMATION; INTRAOCULAR PRESSURE; NONHUMAN; OCULAR PRURITIS; OPTIC NERVE DISEASE; PERIORBITAL FAT ATROPHY; PRIORITY JOURNAL; PRURITUS; RETINA MACULA CYSTOID EDEMA; RISK; UVEITIC GLAUCOMA; UVEITIS; VIRUS REACTIVATION; VISUAL FIELD DEFECT;

GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; PROSTAGLANDINS, SYNTHETIC; UVEITIS;

EID: 80053529205     PISSN: 08820538     EISSN: 17445205     Source Type: Journal    
DOI: 10.3109/08820538.2011.588650     Document Type: Article

References (54)

1. Miyake K, Ota I, Maekubo K, et al. Latanoprost accelerates disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema in early postoperative pseudophakias. Arch Ophthalmol. 1999;117:34-40 (Pubitemid 29056717)
2. Chang JH, McCluskey P, Missotten T, et al. Use of ocular hypotensive prostaglandin analogues in patients with uveitis: Does their use increase anterior uveitis and cystoid macular oedema? Br J Ophthalmol. 2008 Jul;92(7):916-21 (Pubitemid 351969669)
3. Markomichelakis NN, Kostakou A, Halkiadakis I, et al. Efficacy and safety of latanoprost in eyes with uveitic glaucoma. Graefes Arch Clin Exp Ophthalmol. 2009 Jun;247(6):775-80
4. Alm A, Villumsen J, Tornquist P, et al. Intraocular pressure- reducing effect of PHXA41 in patients with increased eye pressure: A one month study. Ophthalmology. 1993; 100:1312
5. Alm A, Stjernschantz J. Scandinavian Latanoprost Study Group: Effects of intraocular pressure and side-effects of 0.005% latanoprost applied once daily, evening or morning: A comparison with timolol. Ophthalmology. 1995; 102:1743
6. Brubaker RF. Mechanism of action of bimatoprost (Lumigan). Surv Ophthalmol. 2001;45:S347-S351
7. Coleman AL, et al. A 3-month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension. Ophthalmology. 2003; 110:2362
8. Simmons ST, Dirks MS, Noecker RJ. Bimatoprost versus latanoprost in lowering intraocular pressure in glaucoma and ocular hypertension: Results from parallel-group comparison trials. Adv Ther. 2004; 21:247
9. Noecker RJ, et al. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol. 2003; 135:55
10. Toris CB, et al. Effects of travoprost on aqueous humor dynamics in patients with elevated intraocular pressure. J Glaucoma. 2007; 16:189
11. Fellman RL, et al. Travoprost Study Group: Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: A 6-month, masked, multicenter trial. Ophthalmology. 2002; 109:998
12. Horsley MD, Kahook MY. Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients. Clin Ophthalmol. 2009;3:291-5
13. Eakins KE. Prostaglandin and non-prostaglandin mediated breakdown of the blood-aqueous barrier. Exp Eye Res. 1977; 25:483
14. Toris CB, Camras CB. Prostaglandins: A new class of aqueous outflow agents. Ophthalmol Clin North Am. 1997; 10:335
15. Bazan NG, Allan G. Signal transduction and gene expression in the eye: A contemporary view of the pro-inflammatory, antiinflammatory and modulatory roles of prostaglandins and other bioactive lipids. Surv Ophthalmol. 1997; 41(suppl 2):S23
16. Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2a analog, on aqueous humor dynamics in human eyes. Ophthalmology. 1993;100:1297-304 (Pubitemid 23274021)
17. Hinz B, et al. Latanoprost induces matrix metalloproteinase-1 expression in human nonpigmentedciliary epithelial cells through a cyclooxygenase-2- dependent mechanism. FASEB J. 2005; 19:1929
18. Lutjen-Drecoll E, Tamm E. Morphological study of the anterior segments of cynomolgus monkey eyes following treatment with prostaglandin F2. Exp Eye Res. 1988; 47:761
19. Gaton DD, Sagara T, Lindsey JD, et al. Increased matrix metalloproteinases1, 2, and 3 in the monkey uveoscleral outflow pathway after topicalprostaglandin F (2 alpha)- isopropyl ester treatment. Arch Ophthalmol. 2001;119(8):1165-1170 (Pubitemid 32730004)
20. Nilsson SF, Drecoll E, Lutjen-Drecoll E, et al. The prostanoid EP2receptor agonist butaprost increases uveoscleral outflow in the cynomolgusmonkey. Invest Ophthalmol Vis Sci. 2006;47(9):4042-4049 (Pubitemid 46044322)
21. Kim JW, et al. Increased human scleral permeability with prostaglandin exposure. Invest Ophthalmol Vis Sci. 2001; 42:1514
22. Krauss AH, Woodward DF. Update on the mechanism of action of bimatoprost: A review and discussion of new evidence. Surv Ophthalmol. 2004; 49(suppl 1):S5
23. Koda N, et al. Synthesis of prostaglandin F ethanolamide by prostaglandin F synthase and identification of Bimatoprost as a potent inhibitor of the enzyme: New enzyme assay method using LC/ESI/MS. Arch Biochem Biophys. 2004; 424:128
24. Filippopoulos T, Paula JS, Torun N,et al. Periorbital changes associated with topical bimatoprost. Ophthal Plast Reconstr Surg. 2008 Jul-Aug;24(4):302-7
25. Parrish RK, Palmberg P, Sheu WP,XLT Study Group.A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: A 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003 May;135(5):688-703 (Pubitemid 36457976)
26. Yousufzai SY, Ye Z, Abdel-Latif AA. Prostaglandin F2 alpha and its analogs induce release of endogenous prostaglandins in iris and ciliary muscles isolated from cat and mammalian species. Exp Eye Res. 1996;63:305-310 (Pubitemid 26325120)
27. Eakins K. Prostaglandin and non-prostaglandin mediated breakdown of blood-aqueous barrier. Exp Eye Res. 1977;25:483-498 (Pubitemid 8205059)
28. Arcieri ES, Santana A, Rocha FN, et al. Blood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia: A 6-month randomized trial. Arch Ophthalmol. 2005 Feb;123(2): 186-92 (Pubitemid 40189705)
29. Stjernschantz JW. From PGF(2alpha)-isopropyl ester tolatanoprost: A review of the development of xalatan: The Proctor Lecture. Invest Ophthalmol Vis Sci. 2001; 42:1134-45 (Pubitemid 32381949)
30. Schumer RA, Camras CB, Mandahl AK. Latanoprost and cystoid macular edema: Is there a causal relation? Curr Opin Ophthalmol. 2000;11:94-100 (Pubitemid 30164028)
31. Smith SL, Pruitt CA, Sine CS, et al. Latanoprost 0.005% and anterior segment uveitis. Acta Ophthalmol Scand. 1999;77:668-672 (Pubitemid 30006808)
32. Warwar RE, Bullock JD, Ballal D. Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients. Ophthalmology. 1998;105:263-268
33. Fechtner RD, et al. Anterior uveitis associated with latanoprost. Am J Ophthalmol. 1998; 126:37
34. Packer M, Fine IH, Hoffman RS. Bilateral nongranulomatous anterior uveitis associated with bimatoprost. J Cataract Refract Surg. 2003; 29:2242
35. Aydin S, Ozcura F. Corneal oedema and acute anterior uveitis after two doses of travoprost. Acta Ophthalmol Scand. 2007; 85:693
36. Kumarasamy M, Desai SP. Anterior uveitis is associated with travoprost. BMJ. 2004; 329:205 (Pubitemid 39013278)
37. Fortuna E, Cervantes-Castañeda RA, Bhat P, Doctor P, Foster CS. Flare-up rates with bimatoprost therapy in uveitic glaucoma. Am J Ophthalmol. 2009 Mar;147(3):565
38. Handa J, Henry JC, Krupin T, et al. . Extracapsular cataract extraction with posterior chamber lens implantation in patients with glaucoma. Arch Ophthalmol. 1987;105:765-9 (Pubitemid 17082535)
39. Keates RH, Steinert RF, Puliafito CA, et al. Long-term follow-up of Nd:YAG laser posterior capsulotomy. J Am Intraocul Implant Soc. 1984; 10: 164-8 (Pubitemid 14120608)
40. Pollack A, Leiba H, Bukelman A, et al. Cystoid macular oedema following cataract extraction in patients with diabetes. Br J Ophthalmol. 1992; 76:221-4
41. Wand M, Gaudio AR, Shields MB. Latanoprost and cystoid macular edema in high-risk aphakic or pseudophakic eyes. J Cataract Refract Surg. 2001; 27:1397
42. Rowe JA, Hattenhauer MG, Herman DC. Adverse side effects associated with latanoprost. Am J Ophthalmol. 1997;124:683-5 (Pubitemid 27469245)
43. Ayyala RS, Cruz DA, Margo CE, et al. Cystoid macularedema associated with latanoprost in aphakic and pseudophakic eyes. Am J Ophthalmol. 1998; 126:602-4 (Pubitemid 28475931)
44. Wand M, Gaudio AR. Cystoid macular edema associated with ocular hypotensive lipids. Am J Ophthalmol. 2002; 133:403
45. Heier JS, Steinert RF, Frederick Jr., AR. Cystoid macular edema associated with latanoprost use. Arch Ophthalmo. 1998; 116:68
46. Callanan D, Fellman RL, Savage JA. Latanoprost-associated cystoid macular edema. Am J Ophthalmol. 1998; 126:134
47. Moroi SE, et al. Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension. Ophthalmology. 1999; 106:1024
48. Lima MC, et al. Visually significant cystoid macular edema in pseudophakic and aphakic patients with glaucoma receiving latanoprost. J Glaucoma. 2000; 9:317
49. Wand M, Gilbert CM, Liesegang TJ. Latanoprost and herpes simplex keratitis. Am J Ophthalmol. 1999; 127:602
50. Kroll DM, Schuman JS. Reactivation of herpes simplex virus keratitis after initiatingbimatoprost treatment for glaucoma. Am J Ophthalmol. 2002;133:401-403 (Pubitemid 34171592)
51. Gordon YJ, et al. The effects of Xalatan on the recovery of ocular herpes simplex virus type 1 (HSV-1) in the induced reactivation and spontaneous shedding rabbit models. J Ocul Pharmacol Ther. 2003; 19:233
52. Kaufman HE, Varnell ED, Thompson HW. Latanoprost increases the severity andrecurrence of herpetic keratitis in the rabbit. Am J Ophthalmol. 1999;127:531-536 (Pubitemid 29215763)
53. Beam G, Reardon G, Zimmerman TJ.,Association between ocular herpes simplex virus,and topical ocular hypotensive therapy. J Glaucoma. 2004;13:361-4 (Pubitemid 39281575)
54. Liesegang TJ, Melton LJ III, Daly PJ, et al. Epidemiology of ocular herpes simplex: Incidence in Rochester, Minn. 1950 through 1982. Arch Ophthalmol. 1989;107:1155-1159 (Pubitemid 19195642)